Skip to main content

Darzalex Side Effects

Generic name: daratumumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jan 28, 2024.

Note: This document contains side effect information about daratumumab. Some dosage forms listed on this page may not apply to the brand name Darzalex.

Applies to daratumumab: intravenous solution.

Serious side effects of Darzalex

Along with its needed effects, daratumumab (the active ingredient contained in Darzalex) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking daratumumab:

More common

Less common

Incidence not known

Other side effects of Darzalex

Some side effects of daratumumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to daratumumab: intravenous solution.


Very common (10% or more): Hypertension (10%)[Ref]


Very common (10% or more): Nausea (27%), diarrhea (16%), constipation (15%), vomiting (14%)[Ref]


Very common (10% or more): Lymphopenia (72%), neutropenia (60%), thrombocytopenia (48%), anemia (45%)[Ref]


Common (1% to 10%): Pneumonia (e.g., streptococcal pneumonia, lobar pneumonia), herpes zoster reactivation[Ref]


Very common (10% or more): Infusion reaction (48%)[Ref]


Very common (10% or more): Decreased appetite (15%)[Ref]


Very common (10% or more): Back pain (23%), arthralgia (17%), pain in extremity (15%), musculoskeletal chest pain (12%)[Ref]

Nervous system

Very common (10% or more): Headache (12%)[Ref]


Very common (10% or more): Cough (21%), upper respiratory tract infection (20%), nasal congestion (17%), dyspnea (15%), nasopharyngitis (15%), vomiting (14%)

Common (1% to 10%): Bronchospasm, dyspnea, hypoxia

Uncommon (0.1% to 1%): Allergic rhinitis allergic, throat irritation[Ref]

Frequently asked questions


1. (2015) "Product Information. Darzalex (daratumumab)." Janssen Biotech, Inc.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.